Mental Health DailyResearch. Evidence. Perspective.Published research on naloxone.
A 2026 umbrella review of 16 systematic reviews covering 371 trials found strong medication evidence for tobacco and opioid use disorders, modest benefits for alcohol use disorder, and no ap…
Read articleA 2026 qualitative case study of 8 top-performing HEALing Communities Study communities linked opioid-response implementation success to representative coalition membership, shared goals, da…
Read articleA 2026 emergency department claims analysis estimated 3.87 million United States ED visits in 2021 where take-home naloxone could have been clinically relevant, compared with 226,453 ED-trea…
Read articleSuboxone is a semisynthetic drug manufactured by Reckitt Benckiser pharmaceuticals for the treatment of opioid dependence. It was introduced to the market in October 2002 and gained populari…
Read articleThere are many new medications that have been engineered specifically for the treatment of opioid dependence. Those dependent on opioids tend to experience debilitating physical and psycholo…
Read articleSubutex and Suboxone are drugs that were approved by the FDA in 2002 for the treatment of opioid dependence. Both drugs contain the active ingredient buprenorphine, a semisynthetic opioid th…
Read articleMethadone was originally developed in Germany during the 1930s as a synthetic alternative to opium. Post World War II, the United States obtained all research records for the substance and n…
Read article
